We indicated that RP-ILD was mainly observed in patients with DM with anti-MDA5 and anti-ARS antibodies or those without MSA in previous studies.12–14 RP-ILD was divided into three groups: MDA5 (positive for anti-MDA5) (39.5%, n=49), ARS (positive for anti-ARS) (39.5%, n=46) (PL-7 13, PL-12 6, OJ 1, Jo-1 18, EJ 8) and MSN (patients who were negative for MSA) (18.5%, n=23). Here, IFIH1 is linked to dermatomyositis.